Q Global Advisors LLC Increases Position in Ascendis Pharma A/S $ASND

Key Points

• Q Global Advisors LLC increased its holdings in Ascendis Pharma A/S by 13.4%, making it the fund's second-largest position, with approximately 31.8% of its total assets in ASND.
• Analysts have set several new price targets for Ascendis Pharma, with UBS Group increasing its target to $307.00, and the stock receiving a consensus rating of "Buy" from fifteen analysts.
• Ascendis Pharma reported earnings of ($0.93) per share, outperforming estimates, with revenue of $216.28 million, significantly exceeding the expected $163.17 million.

Q Global Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 13.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 248,887 shares of the biotechnology company's stock after buying an additional 29,428 shares during the quarter. Ascendis Pharma A/S comprises 31.8% of Q Global Advisors LLC's investment portfolio, making the stock its 2nd biggest position. Q Global Advisors LLC owned about 0.41% of Ascendis Pharma A/S worth $38,792,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. RA Capital Management L.P. lifted its stake in shares of Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock valued at $1,392,221,000 after buying an additional 402,316 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Ascendis Pharma A/S by 4.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after buying an additional 193,688 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Ascendis Pharma A/S by 12.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company's stock valued at $475,970,000 after buying an additional 328,278 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Ascendis Pharma A/S by 7.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,283,207 shares of the biotechnology company's stock valued at $314,330,000 after buying an additional 162,079 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Ascendis Pharma A/S by 0.6% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 1,877,917 shares of the biotechnology company's stock valued at $292,692,000 after buying an additional 10,366 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Wells Fargo & Company restated an "overweight" rating and set a $295.00 price target (up from $289.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. JPMorgan Chase & Co. increased their target price on shares of Ascendis Pharma A/S from $254.00 to $260.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 19th. Wedbush increased their target price on shares of Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Cantor Fitzgerald increased their target price on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. Finally, Royal Bank Of Canada increased their target price on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Fifteen equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $243.36.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock traded up $0.67 on Thursday, hitting $193.68. 214,966 shares of the company's stock traded hands, compared to its average volume of 491,279. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $199.99. The company's fifty day simple moving average is $179.38 and its 200 day simple moving average is $164.88. The stock has a market capitalization of $11.86 billion, a price-to-earnings ratio of -37.52 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.49. The business had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. As a group, sell-side analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.